Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Marbofloxacin
CP Pharma Handelsgesellschaft mbH
QJ01MA93
Marbofloxacin
Solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Cattle, Pigs
Antimicrobial
Expired
2013-02-15
Revised: January 2015 AN: 01100/2014 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbosol 100 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection contains: Active substance: Marbofloxacin 100 mg Excipients: Metacresol 2 mg Monothioglycerol 1 mg For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, yellow solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle, pigs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Cattle: Treatment of respiratory infections caused by susceptible strains of _ Pasteurella _ _multocida, Mannheimia haemolytica_ and _Histophilus somni._ Treatment of acute mastitis caused by _ Echerichia coli_ strains susceptible to marbofloxacin during the lactation period. Pigs: Treatment of Metritis Mastitis Agalactia Syndrome (MMA syndrome, postpartum dysgalactia syndrome, PDS) caused by bacterial strains susceptible to marbofloxacin. 4.3 CONTRAINDICATIONS Do not use in case of bacterial infections with resistance to other fluoroquinolones (cross resistance). Do not use in case of hypersensitivity to the active substance or to any of the excipients. Revised: January 2015 AN: 01100/2014 Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Efficacy data have shown an insufficient efficacy of the product for the treatment of acute mastitis caused by Gram positive strains. 4.5 SPECIAL PRECAUTIONS FOR USE i. Special precautions for use in animals Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoro Read the complete document